NeuroMetrix out of Waltham, MA was cleared by the FDA to bring to the U.S. market its SENSUS transcutaneous electrical nerve stimulator that’s intended for use by diabetics to help manage chronic intractable pain. The SENSUS is attached to the patient’s upper calf and uses proprietary algorithms to generate an electric current that disrupts/modulates nerve pain signals from reaching the brain.
The company is expecting to launch the device later in the year.
Interview with CEO of NeuroMetrix Dr. Shai Gozani…
Press release: NeuroMetrix Receives 510(k) Clearance for SENSUS™ Pain Management Device
Product page: SENSUS…
Flashback: The NC-stat System for Non-Invasive Nerve Conduction Testing